These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 6218942)

  • 61. Identification of molecular forms of plasminogen and plasmin-inhibitor complexes in urokinase-activated human plasma.
    Müllertz S; Thorsen S; Sottrup-Jensen L
    Biochem J; 1984 Oct; 223(1):169-77. PubMed ID: 6208893
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Plasminogen activator release assays.
    Nilsson IM
    Acta Clin Belg; 1977; 32(6):391-7. PubMed ID: 616750
    [No Abstract]   [Full Text] [Related]  

  • 63. Proactivator and activator levels of plasminogen in plasma as measured by caseinolysis.
    Kline DL; Reddy KN
    J Lab Clin Med; 1977 May; 89(5):1153-8. PubMed ID: 140200
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Morning hypercoagulability and hypofibrinolysis. Diurnal variations in circulating activated factor VII, prothrombin fragment F1+2, and plasmin-plasmin inhibitor complex.
    Kapiotis S; Jilma B; Quehenberger P; Ruzicka K; Handler S; Speiser W
    Circulation; 1997 Jul; 96(1):19-21. PubMed ID: 9236409
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Optimum conditions for the stabilization and measurement of tissue plasminogen activator activity in human plasma.
    Chandler WL; Schmer G; Stratton JR
    J Lab Clin Med; 1989 Mar; 113(3):362-71. PubMed ID: 2494279
    [TBL] [Abstract][Full Text] [Related]  

  • 66. The amidolytic activity of the SK-plasminogen complex is enhanced by a potentiator which is generated in the presence of vascular plasminogen activator--role of fibrin degradation products.
    Soria J; Soria C; Bertrand O; Dunn F; Samama M; Bachmann F
    Thromb Haemost; 1982 Jun; 47(3):193-6. PubMed ID: 7051407
    [TBL] [Abstract][Full Text] [Related]  

  • 67. A family with reduced plasminogen activator activity in blood associated with recurrent venous thrombosis.
    Jørgensen M; Mortensen JZ; Madsen AG; Thorsen S; Jacobsen B
    Scand J Haematol; 1982 Sep; 29(3):217-23. PubMed ID: 6890710
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Simplification of a venous occlusion test.
    Mizuno A; Isobe J; Shima K
    Thromb Res; 1991 Apr; 62(1-2):83-92. PubMed ID: 1853308
    [TBL] [Abstract][Full Text] [Related]  

  • 69. The rapid separation and assay of previously unreported plasminogen activators in human euglobulin fractions. The effect of venous occlusion.
    Millar WT; Smith JF
    Thromb Res; 1984 Aug; 35(3):291-9. PubMed ID: 6540485
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Effect of benazepril amlodipine combination on fibrinolysis in hypertensive diabetic patients.
    Fogari R; Preti P; Lazzari P; Corradi L; Zoppi A; Fogari E; Mugellini A
    Eur J Clin Pharmacol; 2003 Aug; 59(4):271-5. PubMed ID: 12830340
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Coordinated induction of plasminogen activator inhibitor-1 (PAI-1) and inhibition of plasminogen activator gene expression by hypoxia promotes pulmonary vascular fibrin deposition.
    Pinsky DJ; Liao H; Lawson CA; Yan SF; Chen J; Carmeliet P; Loskutoff DJ; Stern DM
    J Clin Invest; 1998 Sep; 102(5):919-28. PubMed ID: 9727060
    [TBL] [Abstract][Full Text] [Related]  

  • 72. In vivo effects of urease-producing bacteria involved with the pathogenesis of infection-induced urolithiasis on renal urokinase and sialidase activity.
    du Toit PJ; van Aswegen CH; Nel JA; Steyn PL; Ligthelm AJ; du Plessis DJ
    Urol Res; 1995; 23(5):335-8. PubMed ID: 8839391
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Plasminogen activator inhibitor: a risk factor for myocardial infarction in diabetic patients.
    Gray RP; Yudkin JS; Patterson DL
    Br Heart J; 1993 Mar; 69(3):228-32. PubMed ID: 8461220
    [TBL] [Abstract][Full Text] [Related]  

  • 74. The effect of different exercise intensities on the fibrinolytic system.
    Molz AB; Heyduck B; Lill H; Spanuth E; Röcker L
    Eur J Appl Physiol Occup Physiol; 1993; 67(4):298-304. PubMed ID: 8299595
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Tissue plasminogen activator, plasminogen activator inhibitor-1 and von Willebrand factor in rheumatoid arthritis.
    Wållberg-Jonsson S; Dahlén GH; Nilsson TK; Rånby M; Rantapää-Dahlqvist S
    Clin Rheumatol; 1993 Sep; 12(3):318-24. PubMed ID: 8258230
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Pyelonephritis: renal urokinase and sialidase (neuraminidase) activity in rats fed a standard laboratory diet.
    van Aswegen CH; du Toit PJ; Nel JD; Ligthelm AJ; du Plessis DJ
    Urol Res; 1994; 22(1):57-60. PubMed ID: 8073542
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Pyelonephritis: renal urokinase activity in rats on essential fatty acid diets.
    du Toit PJ; van Aswegen CH; Nel JD; Strasheim B; Becker PJ; du Plessis DJ
    Urol Res; 1994; 22(3):127-30. PubMed ID: 7992455
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Detection and partial characterization of an inhibitor of plasminogen activator in human platelets.
    Erickson LA; Ginsberg MH; Loskutoff DJ
    J Clin Invest; 1984 Oct; 74(4):1465-72. PubMed ID: 6434594
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Generation in plasma of a fast-acting inhibitor of plasminogen activator in response to endotoxin stimulation.
    Colucci M; Paramo JA; Collen D
    J Clin Invest; 1985 Mar; 75(3):818-24. PubMed ID: 3920245
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Determination of C1s-C1 inhibitor complexes in plasma by means of an enzyme linked immunosorbent assay.
    Nilsson T; Bäck O
    Clin Exp Immunol; 1985 Apr; 60(1):178-82. PubMed ID: 3874014
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.